Our research group and others have demonstrated that inhibiting EphB4-ephrinB2 interaction with a soluble protein or a plasmid-based derivative of peptide yields tumor growth retardation, but the magnitude of response is minimal and transient, at best7–9. The gene discussed is EFNB2; the disease is neoplasm.